Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Cacaito who wrote (2800)	3/17/1998 9:48:00 PM
From: bdusa1	Read Replies (1) \| Respond to of 7041

where is Bill!

To: Cacaito who wrote (2800)	3/17/1998 10:37:00 PM
From: phbolton	Read Replies (1) \| Respond to of 7041

Zonagen due diligence, part 2. My first review of the literature indicates that phentolamine is not very active by itself. The combination with papaverine and/or a prostaglandin is more active. There appears to be no possible patent for phentolamine but a patent for a specific formulation appears possible. Phentolamine and papaverine are cheap and readily available chemicals. Current guess: If Pfizer's drug is approved then ZONA will have to prove that their VASOMAX is somehow better in some set of well defined applications. Just as good is not allowed under current FDA rules. Will look into this some more but if Viagra, Pfizer's drug, is approved then its hard to see how VASOMAX will be a success. There may be some other things in the pipline but I'll need the investors packet from ZONA to be informed about them.